IDIOPATHIC PULMONARY FIBROSIS

This study tested an experimental drug called GKT137831 in 58 people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The drug aims to reduce lung damage caused by harmful molecules called reactive oxygen species. Researchers measured cha…

This Phase 3 trial tested whether an inhaled drug called treprostinil (Tyvaso) could slow the loss of lung function in 598 adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. Participants inhaled the drug or a placebo four times daily for 52 weeks. The ma…

This early-phase study tested a purified green tea extract called EGCG in 50 people with idiopathic pulmonary fibrosis (IPF) who were already taking standard medications. The main goal was to check if EGCG is safe and how it interacts with their usual drugs. Participants took EGC…

This phase 2 trial tested an experimental tablet called HSK44459 in 186 adults with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. Participants took one of three doses of the drug or a placebo twice daily for 12 weeks. The main goal was to see if the dr…

This study tested whether the antioxidant N-acetylcysteine (NAC) can slow lung decline in people with idiopathic pulmonary fibrosis (IPF) who have a specific gene variant (TOLLIP TT). Over 200 participants took NAC or a placebo for 24 months. The goal was to see if NAC delays wor…

This study tested a new cell therapy called REGEND001 for people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. The therapy uses special lung cells to try to repair damaged tissue. In this phase 2 trial, 23 participants received either the cell therapy or a pla…

This study tests an experimental oral drug, BI 1819479, in 322 adults with idiopathic pulmonary fibrosis (IPF). Participants receive one of three doses or a placebo for 6 to 12 months. The main goal is to see if the drug can slow the yearly decline in lung function, measured by b…

This study tested an experimental drug called MN-001 (tipelukast) in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants took either the drug or a placebo twice daily for six months, then everyone could take the drug for an…

This early study tested whether injecting human umbilical cord stem cells into the lungs is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Seventeen patients received different doses through a bronchoscope. The m…

This phase 2a trial tested a drug called PLN-74809 in 10 people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. Participants took the drug or a placebo daily for 12 weeks. The study used a special PET/MRI scan to measure collagen (scar t…

This early-stage trial tested the safety and tolerability of a new drug called BI 1015550 (Nerandomilast) in 15 people with idiopathic pulmonary fibrosis (IPF). Participants took either the drug or a placebo twice daily for up to 12 weeks. The study aimed to see if the drug is sa…

This study tested an oral drug called GRI-0621 in 35 adults with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. Participants took either the drug or a placebo daily for 12 weeks. The main goals were to check safety and m…

This large Phase 3 trial tested whether the drug BI 1015550 (nerandomilast) can help people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. Over 1,100 adults aged 40 and older took either a low or high dose of the dr…

This study tested an inhaled drug called ARO-MMP7 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal was to check safety and how the body handles the drug. About 105 participants took p…

This Phase 2 study tested an experimental oral drug called TTI-101 in 100 people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. Participants took either TTI-101 or a placebo daily for 12 weeks. The main goal was to check sa…

This early-stage study tested a new drug called HuL001 in 24 people, including healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. The main goal was to check safety and how the body handles the drug. This is a first step to see if Hu…

This study tested whether a special lung MRI can replace CT scans for diagnosing idiopathic pulmonary fibrosis (IPF), a scarring lung disease. Researchers compared MRI to standard CT in 60 patients to see if MRI could spot the same key signs of IPF without using radiation. The go…

This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …

This early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…

This study tested the drug letermovir to prevent CMV infection in 15 adults who had a lung transplant for idiopathic pulmonary fibrosis (IPF). Participants took letermovir daily for 6 or 12 months depending on their CMV risk. The goal was to see if the drug could prevent CMV infe…

This study tested whether an extended-release form of nalbuphine, a pain medication, can reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF). 165 participants received either different doses of the drug or a placebo for 6 weeks. The main goal was to see if …

This study looked at whether giving extra oxygen (40%) during exercise helps people with idiopathic pulmonary fibrosis (IPF) who do not have low oxygen at rest but do get low oxygen when active. Fifteen stable IPF patients completed exercise tests while breathing either oxygen or…

This study looked at whether breathing 60% oxygen during exercise helps people with idiopathic pulmonary fibrosis (IPF) who are taking nintedanib. 78 participants exercised on a bike or walked while getting either high oxygen or standard care. The goal was to see if they could ex…

This study followed 18 people in Spain with idiopathic pulmonary fibrosis (IPF) or other progressive lung scarring who were taking nintedanib (OFEV) and had developed diarrhea. The goal was to see if the diarrhea could be controlled after 12 weeks while staying on the full dose. …

This study tested whether low-dose morphine can reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Forty-four participants received either morphine or a placebo for two weeks, then switched after a week off. The goal was to see if…

This study tested a drug called orvepitant to see if it can reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 80 adults with IPF and persistent cough took either orvepitant or a placebo in two separate periods, and researche…

This study looked at whether certain genes make people who are regularly around pigeons more likely to develop a type of lung disease called hypersensitivity pneumonitis. Researchers analyzed the DNA of 475 pigeon fanciers to find genetic markers linked to lung scarring. The goal…

This study looked at how a new drug called HEC585 interacts with two existing medicines for idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Thirty-three healthy adults took part to measure drug levels and safety. The goal was to see if combining these drugs cause…

This study tested whether a new type of PET scan can measure how the supplement EGCG (found in green tea) affects collagen buildup in the lungs of people with idiopathic pulmonary fibrosis (IPF). Twelve participants who were already in a larger EGCG study received an injection of…

This completed study in France tracked over 10,000 people with idiopathic pulmonary fibrosis to see how long they continued taking antifibrotic drugs (nintedanib or pirfenidone). The goal was to measure the percentage still on treatment after 30 months and identify factors linked…

This study followed 51 people with idiopathic pulmonary fibrosis (IPF) for 6 months to understand how their shortness of breath changes over time. Researchers measured both the physical sensation and the emotional impact of breathlessness, and looked at how these relate to lung f…

This study looked at 250 people to understand why some smokers develop a rare lung condition called combined pulmonary fibrosis and emphysema (CPFE). Researchers compared telomere length and genetic mutations in patients with CPFE, those with only fibrosis or emphysema, and healt…

This study tested whether a device called MYOTRACE, which measures how hard a person's breathing muscles are working, can help doctors assess patients with respiratory diseases. 56 adults with conditions like COPD or asthma were included. The goal was to see if the device's readi…

This completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…

This study looked at whether a device that delivers rapid puffs of air (intrapulmonary percussive ventilation) can help inhaled medication reach scarred lung areas in people with idiopathic pulmonary fibrosis (IPF). Nine participants inhaled a radioactive tracer with and without …